Metraipolis › archive › dc_da24422e7581

Ocrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report — Europe PMC PMID:42770063

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42770063
DOI
10.7759/cureus.116594
License (as archived)
solo-consultazione
Archived
2026-10-08T02:28:43.330Z
SHA-256 of the archived text
0190ebf54baed46408d2d4100ba697ab5300782fe5865e93f3b7fcee93480224
Stable URL of this page
https://metraipolis.com/documento/dc_da24422e7581

How to cite

Ocrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report — Europe PMC PMID:42770063 — Europe PMC (en), https://europepmc.org/article/MED/42770063 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_da24422e7581 (Metraipolis archive dc_da24422e7581, sha256 0190ebf54baed46408d2d4100ba697ab5300782fe5865e93f3b7fcee93480224)
BibTeX
@misc{dcda24422e7581,
  title = {Ocrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report — Europe PMC PMID:42770063},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42770063},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_da24422e7581; sha256 0190ebf54baed46408d2d4100ba697ab5300782fe5865e93f3b7fcee93480224},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42770063. Agents can read the archived copy with the MCP tool read_document.